Goldfinch Biopharma is a precision medicine kidney company. The company focuses on its mission to deliver disease-modifying precision medicines that bring hope and renewed quality of life to the people who are with kidney disease. It aspires to end dialysis and save kidneys.
Goldfinch is applying precision medicine to discovering, developing and commercializing disease, and also modifying kidney disease treatments. The company believes its approach enables it to uncover subsets of patients based on genetic and environmental factors within heterogenous kidney diseases.
Goldfinch has a pipeline of novel, precision medicine product candidates that are targeting kidney diseases with challenging and unmet medical needs. Its lead program, GFB-887, has been designed for the treatment of people with focal segmental glomerulosclerosis that is caused by an overactivation of the TRPC5-Rac1 pathway.